PULMIPROVE 62.5 MG 30 F.C. TABS

Pharmacology Endothelian receptor antagonist that blocks endothelin receptors on endothelium and vascular smooth muscle (stimulation of these receptors is associated with vasoconstriction). Bosentan blocks both ETA and ETB receptors with a slightly higher affinity for the A subtype. Indications Pulmonary arterial hypertension: Treatment of pulmonary artery hypertension (PAH) (WHO Group I) in patients with WHO/NYHA Class II III or IV symptoms to improve exercise capacity and decrease the rate of clinical deterioration. Note: According to treatment guidelines from the Fifth World Symposium on Pulmonary Hypertension (WSPH) only a small number of PAH patients with WHO-FC IV symptoms (ie severely ill patients) were included in clinical trials therefore most experts consider bosentan second-line therapy in these patients (WSPH [Gail� 2013]).